Icure Pharmaceutical Incorporation (175250) - Total Liabilities

Latest as of June 2025: ₩80.55 Billion KRW ≈ $54.59 Million USD

Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has total liabilities worth ₩80.55 Billion KRW (≈ $54.59 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Icure Pharmaceutical Incorporation - Total Liabilities Trend (2015–2024)

This chart illustrates how Icure Pharmaceutical Incorporation's total liabilities have evolved over time, based on quarterly financial data. See Icure Pharmaceutical Incorporation current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Icure Pharmaceutical Incorporation Competitors by Total Liabilities

The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their total liabilities.

Company	Country	Total Liabilities
Northwest Copper Corp V:NWST	Canada	CA$1.66 Million
NTPM Holdings Bhd KLSE:5066	Malaysia	RM484.30 Million
American Creek Resources Ltd V:AMK	Canada	CA$30.45K
Bactiguard Holding AB (publ) ST:BACTI-B	Sweden	Skr225.74 Million
Nam Liong Global Corp TWO:5450	Taiwan	NT$1.72 Billion
Nila Spaces Limited NSE:NILASPACES	India	Rs1.94 Billion
TAPEX INC KO:055490	Korea	₩39.20 Billion
Nahar Industrial Enterprises Limited NSE:NAHARINDUS	India	Rs6.90 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down Icure Pharmaceutical Incorporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Icure Pharmaceutical Incorporation market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.71	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Icure Pharmaceutical Incorporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Icure Pharmaceutical Incorporation (2015–2024)

The table below shows the annual total liabilities of Icure Pharmaceutical Incorporation from 2015 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩72.62 Billion ≈ $49.22 Million	-31.84%
2023-12-31	₩106.54 Billion ≈ $72.20 Million	-20.76%
2022-12-31	₩134.45 Billion ≈ $91.11 Million	+12.33%
2021-12-31	₩119.69 Billion ≈ $81.11 Million	+44.22%
2020-12-31	₩82.99 Billion ≈ $56.24 Million	-29.82%
2019-12-31	₩118.27 Billion ≈ $80.15 Million	+225.73%
2018-12-31	₩36.31 Billion ≈ $24.61 Million	-0.32%
2017-12-31	₩36.43 Billion ≈ $24.69 Million	+149.76%
2016-12-31	₩14.58 Billion ≈ $9.88 Million	-27.76%
2015-12-31	₩20.19 Billion ≈ $13.68 Million	--

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$54.96 Million

₩81.09 Billion KRW

Market Cap Rank

#21611 Global

#1275 in Korea

Share Price

₩2170.00

Change (1 day)

+11.91%

52-Week Range

₩1805.00 - ₩2170.00

All Time High

₩23730.97